Today in a press release, Harrow announced the Series A financing of their (formerly) wholly owned subsidiary, Melt Pharmaceuticals. This is a very positive announcement for Harrow and I believe the value of MELT is in no way reflected...
Tailwinds' Take: very important press release. Not only did they need capital to grow, but this shows they are delivering on their promises. Perhaps the even more important information, however, is contained in the subtitle, "product innovations to broaden...
TORONTO, ON–(May 10, 2017) – Patriot One Technologies Inc. (TSX VENTURE: PAT) (OTCQB: PTOTF) (FRANKFURT: 0PL) (“Patriot One” or the “Company”), developer of the revolutionary award-winning PATSCAN CMR concealed weapons detection system, today announced a reseller agreement with Information...
Tailwinds' Take: if trends continue, the 90 day data should be very positive. We continue to believe that HJLI represents a compelling risk/reward scenario in which both products are exceeding expectations while the market cap of the Company remains...
OLDWICK, N.J., Aug. 6, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2019 and provided a business update. "The data from the...
Tailwinds' Take: the revenue generated by these sales is probably only a couple hundred thousand in Q4 at best, so don't get too excited about that. However, as George said, it's the validation and new opportunity creation that will...
IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and consumer product TRU NIAGEN®, announced today the expansion of its partnership with A.S. Watson Group until September 2021,...
Tailwinds' Take: additional data from the ongoing ResearchDx partnership, which is intended to certify Cchek as a CLIA approved diagnostic, will be presented. Anixa remains on track to deliver their novel AI based prostate diagnostic to the market by...
Tailwinds' Take: Provention continues to build a team around the massive opportunity of tepluzimab. Hoitt has an impressive resume. We view his addition very positively. OLDWICK, N.J., Jan. 8, 2020 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage...
On Friday, my favorite little boom or bust biotech, Bioasis, reported their results. There is very little to learn from looking at the numbers; this is a tiny, pre-revenue company. However, in the MD&A section of the filing was...
DFC Advisory Services LLC (dba Tailwinds Research) is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.